OBJECTIVES: CD62L was evaluated as a determinant of human pre-effector T cells.
STUDY DESIGN AND SETTING: Phenotype and cytokine secretion profiles of CD62L cells were determined based on activation status.
RESULTS: CD62LLow T cells demonstrated significantly higher secretion of interleukin (IL)-10 and interferon (IFN)-Γ than did CD62LHigh T cells. After activation, the majority of cells expressed high levels of the CD62L surface marker. Postactivation levels of IL-10 production remained elevated or unchanged. In a murine B16 melanoma model, freshly isolated CD62LLow tumor draining lymph nodes (TDLN) T cells showed increased secretion of IL-2 and IL-4 but not of IL-10 or IFN-γ. The surface expression of CD62L and cytokine secretion patterns were maintained after activation with concomitant increases in IL-10.
CONCLUSION: Our results provide evidence that CD62LLow T cells in TDLNs of progressively growing squamous cell carcinoma of the head and neck differ phenotypically and functionally from those of mouse origin.
SIGNIFICANCE: Characterization of this human CD62LLow T cell population provides initial insight regarding novel surface markers in TDLN T cells that might correlate with antitumor reactivity.
Get full access to this article
View all access options for this article.
References
1.
ShuSStromeSEKraussJC et al. Tumor-draining lymph nodes as a source for generating therapeutic immune T cells. In: ChangAEShuS, editors. Immunotherapy of cancer with sensitized T lymphocytes. Austin, TX: RG Landes Co.; 1994. p. 1–14.
2.
RosenbergSA. The immunotherapy and gene therapy of cancer. J Clin Oncol1992;10:180–99.
3.
RosenbergSAYanelliJRYangJC et al. Treatment of patients with metastatic melanoma using autologous tumor-infiltrating lymphocytes and interleukin-2. J Natl Cancer Inst1994;86:1159–66.
4.
ChangAArugaACameronMJ et al. Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2. J Clin Oncol1997;15:796–807.
5.
PlautzGEBarnettGHMillerDW et al. Systemic T cell adoptive immunotherapy of malignant gliomas. J Neurosurg1998;89:42–51.
6.
KagamuHTouhaliskyJEPlautzGE et al. Isolation based on L-selectin expression of immune effector T cells derived from tumor-draining lymph nodes. Cancer Res1996;56:4338–42.
7.
KagamuHShuS. Purification of L-selectin (low) cells promotes the generation of highly potent CD4 anti-tumor effector T lymphocytes. J Immunol1998;160:3444–52.
8.
KjaergaardJShuS. Tumor infiltration by adoptively transferred T cells is independent of immunologic specificity but requires down-regulation of L-selectin expression. J Immunol1999;163:751–9.
9.
KawashimaHWatanabeNHiroseM et al. Vascular and non-vascular ligands for L-selectin. Cell Adhes Commun1998;6:135–9.
10.
GallatinWMWeissmanILButcherEC. A cell-surface molecule involved in organ-specific homing of lymphocytes. Nature1983;304:30–4.
11.
ArbonesMLOrdDCLeyK et al. Lymphocyte homing and leukocyte rolling and migration are impaired in L-selectin-deficient mice. Immunity1994;1:247–60.
12.
HoffmanHTKamellLHFunkGF et al. The National Cancer Database report on cancer of the head and neck. Arch Otolaryngol Head Neck Surg1998;124:951–62.
13.
FooteRLOlsenKDDavisDL et al. Base of tongue carcinoma: Patterns of failure and predictors of recurrence after surgery alone. Head Neck1993;15:300–7.
14.
JohnsonJTWagnerRLMyersEN. A long-term assessment of adjuvant chemotherapy on outcome of patients with extracapsular spread of cervical metastases from squamous carcinoma of the head and neck. Cancer1996;77:181–5.
15.
OlsenKDCarusoMFooteRL et al. Primary head and neck cancer: Histopathologic predictors of recurrence after neck dissection in patients with lymph node involvement. Arch Otolaryngol Head Neck Surg1994;120:1370–4.
16.
StromeSESauvaABrissettAE et al. Squamous cell carcinoma of the tonsils: A molecular analysis of HPV associations. Clinical Cancer Research (In press).
17.
NakaoMShichijoSImaizumiT et al. Identification of a gene coding for a new squamous cell carcinoma antigen recognized by the CTL. J Immunol2000;164:2565–74.
18.
StromeSEMartinEFliesD et al. Enhanced therapeutic potential of adoptive immunotherapy by in vitro CD28/4–1BB costimulation of tumor reactive T cells against a poorly immunogenic, MHC class I-negative AP9 melanoma. J Immunother2000;23:430–7.
19.
FavreNBordmannGRudinW. Comparison of cytokine measurements using ELISA, ELISpot and semi-quantitative RT-PCR. J Immunol Methods1997;204:57–66.
